Autotelic Bio is a clinical stage pharmaceutical company focused on bringing novel nucleic acid therapies to the market. Our proprietary RNA interference (RNAi) ASO platform ASODE & CATs (Conjugated ASO Targeting Solution) allows for selective targeting and the precise optimization of ASO(Antisense Oligonucleotide) designed to potentially deliver greater efficacy, safety, and tolerability compared to other RNAi medicines. Our main therapeutic targets are Immuno-oncology, IPF and also we are developing FDCs with synergy effect.